Результаты поиска

Long-term outcome after combined kyphoplasty and intraoperative radiotherapy (Kypho-IORT) for vertebral tumors.

IntroductionThe spine represents the site which is most frequently affected by bone metastases in patients with systemic cancer. Of all local treatment options, combined kyphoplasty and intraoperative radiotherapy (Kypho-IORT) provides both, instantaneous stabilization and immediate pain relief. We here report on the long-term outcomes of the largest cohort treated with Kypho-IORT to date.MethodsBetween 2009 and 2019 a total of 104 patients underwent Kypho-IORT to vertebral tumors in the thoracic, lumbar, or sacral spine with transpedicular kyphoplasty and intraoperative irradiation with a nee

Factors influencing physical activity participation among people living with or beyond cancer: a systematic scoping review.

BackgroundIt has been posited that physical activity (PA) has the potential to improve health outcomes and the health-related quality of life of people living with or beyond cancer. Despite the well-documented health benefits of PA, there is a low level of PA among cancer patients. A systematic scoping review was conducted to investigate attitudes, perceptions, preferences and barriers vs. facilitators to cancer patients' PA participation.MethodsA systematic search was performed across four automated databases (PubMed, Embase, PsycINFO and Medline) in keeping with the PRISMA guideline. All can

Cardiotoxicity in people undergoing cancer treatment - the role of the oncology nurse.

Cardiotoxicity is a significant complication of cancer treatment, and this review describes the cardiovascular risks associated with various therapies and emphasizes the crucial role of oncology nurses in managing these risks. Many cancer treatments, including cytotoxic therapies, radiation, targeted therapies, and immune-modulatory drugs, have been shown to increase the likelihood of cardiovascular toxicity, leading to conditions such as acute coronary syndrome, heart failure, and atrial fibrillation. Guidelines are now available to reduce treatment-related cardiovascular toxicity (CTR-CVT) a

Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma.

Multiple myeloma (MM) has a five-year prevalence worldwide of 230,000 people and is known as the second most common hematological malignancy within the United States. Extensive research has been conducted to gain a wide range of treatment strategies, providing hope to these patients. Combination therapy using chemotherapy, monoclonal antibodies, and immunomodulatory drugs are the current management of choice. After the introduction of chimeric antigen receptor (CAR) T cell therapy, promising results have been evidenced. In this therapy, T cells are derived from the patient and modified in-vitr

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.

INTRODUCTION: Multiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population.Over the last 10 years, patient outcomes have improved. However, this is less apparent in older, less fit patients, who are ineligible for stem cell transplant. Research is required in this patient group, taking into account frailty and aiming to improve: treatment tolerability, clinical outcomes and quality of life. METHODS AND ANALYSIS: Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma is a nati

The impact of myelosuppression on quality of life of patients treated with chemotherapy.

Side effects from chemotherapy-induced myelosuppression can negatively affect patients' quality of life (QoL). Neutropenia increases infection risk, and anemia frequently results in debilitating fatigue. Additionally, the bleeding risk associated with thrombocytopenia can lead to fear and anxiety. However, traditional interventions for myelosuppression fall short of the ideal. Granulocyte colony-stimulating factors reduce the risk of severe neutropenia but commonly lead to bone pain. Erythropoiesis-stimulating agents are not always effective and may cause thromboembolic events, while transfusi

Client preferences in noncommunicable diseases management in Australia: A scoping review.

Noncommunicable diseases (NCD) are the leading causes of mortality in Australia. Understanding clients' preferences is essential to implement effective care models that revitalize utilization of services. This study aims to review existing evidence on client preferences of service delivery among people with NCD in Australia. We followed PRISMA extension for scoping review. Articles conducted with discrete choice experiment were included. Clients with NCD in general or one of the five major diseases: cardiac diseases, diabetes, cancer, chronic respiratory diseases, and mental health disorders.

Biosimilars in Oncology: Latest Trends and Regulatory Status.

Biologic-based medicines are used to treat a variety of diseases and account for around one-quarter of the worldwide pharmaceutical market. The use of biologic medications among cancer patients has resulted in substantial advancements in cancer treatment and supportive care. Biosimilar medications (or biosimilars) are very similar to the reference biologic drugs, although they are not identical. As patent protection for some of the most extensively used biologics begins to expire, biosimilars have the potential to enhance access and provide lower-cost options for cancer treatment. Initially, r

A Review on the Multidisciplinary Approach for Cancer Management in the Eastern Mediterranean Region: A Focus on Nutritional, Lifestyle and Supportive Care.

Cancer is one of the leading causes of global morbidity and mortality and one of the most challenging global health conditions, impacting the lives of millions every year. The Eastern Mediterranean Region (EMR) is not on track to achieve the sustainable development goal (SDG) target 3.4 which aims to reduce premature mortality (i.e., before the age of 70 years) for non-communicable diseases (NCDs), including cancer, by a third by year 2030; instead, it is projected that the EMR will experience the least progress towards achieving this target. This review therefore highlights the importance of

Renal Transplantation in HIV-positive and HIV-negative People With Advanced Stages of Kidney Disease: Equity in Transplantation.

BackgroundPeople with HIV are at a greater risk of end-stage kidney disease than the general population. Considering the risk of death after end-stage kidney disease, access to renal transplantation in people with HIV is critically important.MethodsWe included all adult patients on chronic dialysis in Ontario, Canada, between 1 April 2007 and 31 December 2020. We determined the probability of kidney transplantation with competing risk of death over time since the initiation of dialysis by calculating the adjusted subdistribution hazard ratios (sdHR; 95% confidence interval [CI]). We also compa

Gabapentinoids and unexplained death in general practice: Case series and feasibility study arising from a critical incident.

BACKGROUND: Prescribing epidemiology in general practice shows gabapentinoid drugs to be independently associated with unexpected, drug-related death. There is an increasing trend of gabapentinoid deaths throughout Europe and North America. OBJECTIVES: The overall aim of this study was to assess how patient, practice and health system factors might be associated with gabapentinoid prescribing in primary care. METHODS: Case series following a critical incident of an unexpected death in a patient prescribed a gabapentinoid drug in a single general practice. Unexpected and expected deaths in pa

Совпадение в полном тексте источника
… Ethics approval and consent to participate This study was done as a clinical audit for the Irish College of General Practitioners (ICGP) professional competence scheme 2024/5, consistent with Section 4.1.4 ‘Activities that do not require REC approval’ from HSE National Framework for Governance, Management …

Symptom tracking made simple? Observational data on the clinical use of the PERS2ON score in cancer patients receiving palliative care.

ContextA standardized assessment of symptoms is essential for individualized palliative care (PC). While numerous tools exist, many are too complex for daily clinical use.ObjectiveThe PERS2ON score was developed as a brief and practical tool to assess symptom burden in PC. This study aimed to evaluate its feasibility in a rural hospital setting, although it did not include formal feasibility metrics such as recruitment or adherence rates.MethodsPatients admitted to the palliative care unit of a rural hospital were assessed using the PERS2ON score, which includes seven items: pain, eating, reha

Treatment of Multiple Myeloma in Elderly Patients: A Review of Literature and Practice Guidelines.

Multiple myeloma (MM) is a clonal disorder of malignant plasma cells that comprises approximately 10% of hematologic malignancies. With median age of 66 at the time of presentation, multiple myeloma is predominantly a disease of the elderly. The availability of new combination regimens and the enhanced safety of autologous hematopoietic stem cell transplant has increased the treatment options for elderly patients with multiple myeloma. We provide a summary of data supporting the current management of elderly patients with newly diagnosed multiple myeloma.

Cannabis in Hematology Survey Study (CHESS): A Longitudinal Investigation on Uses, Attitudes, and Outcomes of Cannabis Among Hematology Patients Undergoing Hematopoietic Stem Cell Transplant.

Cancer patients use cannabis for medicinal purposes; however, few studies have examined hematology patients' use of cannabis and no research to our knowledge has investigated the use of cannabis amongst hematology patients before and after hematopoietic stem cell transplant (HCT). The purpose of this longitudinal survey study was to assess aspects of cannabis use in patients who underwent HCT. Eligible patients (N = 30) completed two surveys before and 90 days following their HCT. The surveys inquired about several aspects of cannabis (e.g., rate of use, beliefs and attitudes, access to inform

Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence.

ObjectivesTo assess the relationship between UK-based patient organisation funding and companies' commercial interests in rare and non-rare diseases in 2020.DesignRetrospective analysis of the value and volume of payments from pharmaceutical companies to patient organisations in the UK matched with data on the conditions supported by patient organisations and drugs in companies' approved portfolios and research and development pipelines.SettingUK.Participants74 pharmaceutical companies making payments to 341 UK-based patient organisations.Main outcome measuresAlignment between the commercial i

Early palliative care for solid and blood cancer patients and caregivers: Quantitative and qualitative results of a long-term experience as a case of value-based medicine.

IntroductionCancer patients and their caregivers have substantial unmet needs, that negatively impact the clinical outcome and quality of life. However, interventions aimed to address such needs are still suboptimal, failing to answer the recent healthcare call for the adoption of value-based models of care. In the case of incurable oncologic and hematologic cancers, a value-based model of care should plan advanced care on patients' needs and include the quality of death as an outcome. The integration of early palliative care into standard oncologic care for patients with advanced cancers repr

Prevalence and determinants of sleep problems in cancer survivors compared to a normative population: a PROFILES registry study.

PURPOSE: To (1) identify the prevalence of sleep problems in cancer survivors across cancer types and survivorship durations compared to a normative population and (2) determine demographic, clinical, lifestyle, and psychosocial determinants. METHOD: Cancer survivors diagnosed between 2008 and 2015 (N = 6736) and an age- and sex-matched normative cohort (n = 415) completed the single sleep item of the EORTC QLQ-C30: Have you had trouble sleeping? Participants who responded with "quite a bit"/ "very much" were categorized as poor sleepers. A hierarchical multinomial logistic regression was use

Effects of nurse-led symptom management in chronic myeloid malignancies: a randomized trial.

PurposeChronic hematological malignancies progress slowly, potentially manifesting symptoms spanning months to years. HM-PRO is developed as a comprehensive clinical tool for assessing symptoms in hematology. The aim was to investigate the effect of a nurse-led systematic approach to symptom identification and management using HM-PRO in outpatient care in patients with chronic hematological malignancies.MethodsThis is a randomized trial including 94 patients to investigate an intervention comprising (1) HM-PRO data collection, (2) HM-PRO assessment guided by an algorithm, and (3) nurse-led tai

Мы игнорируем сексуальные различия в гематологии? Призыв к совершенствованию отчетности.

Существуют явные различия по признаку пола в частотности, факторах риска и смертности от большинства гематологов (ГМ). Несмотря на известные различия в физиологии, гематопоисеях, молекулярных профилях, фармакокинетике наркотиков, токсичности, связанной с лечением, и опыте лечения, мужчины и женщины получают стандартизованное и одинаковое лечение большинства ТМ. Предыдущая опубликованная работа продемонстрировала различия в представленности женщин в клинических испытаниях на рак и выявила недостаток информации о результатах дифференцированного лечения и токсичности в разбивке по полу. Мы проана

Burden of Disease and Cost of Illness of Triple-Negative Breast Cancer in Portugal.

BackgroundTriple-negative breast cancer accounts for 15% of all breast cancer cases, and it has a lower survival rate and higher incidence of early recurrence, particularly during the first 10 years after diagnosis.ObjectiveThis study aimed to estimate the cost and burden of triple-negative breast cancer among the female population in 2019 in Portugal from a societal perspective.MethodsThe prevalence of triple-negative breast cancer was calculated using a cumulative incidence model on the basis of national epidemiological data. The burden of disease was expressed as disability-adjusted life ye